UniQure seeks FDA approval for Huntington's disease gene therapy

UniQure (QURE) surged 78% on June 16 after the FDA approved analyses from its AMT-130 Huntington's disease gene therapy clinical study. Barclays subsequently upgraded QURE to 'Overweight', citing the program's advancement. On June 17, QURE was listed among the '10 Best Healthcare Stocks to Buy According to Wall Street Analysts'.

This narrative drives investor interest in gene therapy stocks, particularly those focused on rare diseases like Huntington's. It also puts pressure on competitors like Sangamo Therapeutics (SGMO) and Intellia Therapeutics (NTLA) to demonstrate progress in their own gene therapy pipelines.

Next, watch for QURE's FDA decision on its Biologics License Application (BLA) for AMT-130, expected in late 2021. Additionally, monitor QURE's Q2 earnings on August 5, as analysts will likely query management on the AMT-130 approval process and potential launch plans.